---
layout: default
title: Apis Mellifera Aralia Racemosa Root Ascorbic Acid 
parent: 僅模型預測 (L5)
nav_order: 345
evidence_level: L5
indication_count: 0
---

# Apis Mellifera Aralia Racemosa Root Ascorbic Acid 
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Component Immunomodulatory Complex: No Repurposing Prediction Available

## One-Sentence Summary

This product is a 18-component mixture comprising plant extracts, minerals, vitamins, and immune mediators (including IL-12, IFN-γ, IL-10, and histamine dihydrochloride), currently not registered in Taiwan or the US market.
The TxGNN model was unable to generate any repurposing prediction for this candidate — likely due to the absence of a mappable DrugBank entry or a single active pharmacological entity.
Without a prediction output or existing indication data, evidence-based evaluation cannot proceed at this time.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available — no regulatory license on record |
| Predicted New Indication | Not available — no TxGNN prediction generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (model prediction only — in this case, no prediction generated) |
| US Market Status | ✗ Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No TxGNN prediction was generated for this candidate, so a standard mechanism-to-indication bridging analysis cannot be performed.

The 18 listed ingredients span several pharmacological categories: cytokines and immune mediators (Human Interleukin-12, Interferon Gamma-1b, Interleukin-10, Histamine Dihydrochloride), plant-derived immunomodulators (Elderberry, Rosa Canina, Plantago Major, Aralia Racemosa, Black Currant, Melilotus, Onion, Helianthemum Canadense), minerals (Copper, Manganese Gluconate, Silver Nitrate), a vitamin (Ascorbic Acid), and other botanicals (Apis Mellifera, Euphorbia Resinifera Resin). This composition pattern is typical of homeopathic or isopathic immunostimulant preparations, in which active components are used at sub-pharmacological or diluted concentrations.

The absence of a DrugBank ID and the multi-ingredient nature of the formulation are the most likely reasons TxGNN could not map this candidate to its knowledge graph. TxGNN operates on single-molecule nodes; a complex heterogeneous mixture without a defined principal active ingredient cannot be represented as a graph node and therefore yields no output.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## US Market Information

This product has no US FDA-approved applications on record. No NDA, BLA, or OTC monograph entries were retrieved.

---

## Safety Considerations

Please refer to the package insert for safety information.

> No safety data was retrieved from any queried source (TFDA label, DDI database, or DrugBank). Key warnings, contraindications, and drug interaction data are all classified as data gaps and cannot be reported at this time.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN pipeline returned no predicted indication for this candidate, and the product carries no regulatory approval in Taiwan or the US. Proceeding without a defined target indication and without safety labeling data would not be actionable.

**To proceed, the following is needed:**

- **Identify the principal active ingredient (PAI):** Determine which component — most likely one of the immune mediators (IL-12, IFN-γ, or histamine dihydrochloride) — is the pharmacologically active driver, and re-submit it as a single-entity TxGNN query.
- **Retrieve MOA data:** Query DrugBank individually for each component to establish mechanism of action, particularly for the cytokine and botanical ingredients.
- **Clarify regulatory status:** Confirm whether this product is a registered homeopathic formulation, an investigational biologic, or a nutraceutical — as the evaluation pathway differs substantially between categories.
- **Obtain safety label:** Retrieve the full prescribing information or product monograph to enable S1 safety screening.
- **Re-run TxGNN:** Once a mappable single active entity is identified, re-execute the prediction pipeline to generate a repurposing candidate score.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

